From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

Navigating Maximum Fair Price in Prostate Cancer Care

In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer care in community oncology. They review therapies selected for MFP regulation, key implementation timelines, and share practical steps oncology providers and practices can take now to prepare. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.   Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

IMforte Trial: Redefining First-Line Maintenance Therapy in ES-SCLC

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 2025. Tune in to hear expert perspectives on how this new indication will influence clinical practice and improve outcomes for ES-SCLC patients. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

How Comprehensive Molecular Profiling and AI are Shaping the Future of Cancer Care

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical validation and regulatory approval. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.